MULTIPLEX PCR FOR THE DETECTION OF MYCOPLASMA-FERMENTANS, M-HOMINIS AND M-PENETRANS IN CELL-CULTURES AND BLOOD-SAMPLES OF PATIENTS WITH CHRONIC-FATIGUE-SYNDROME
Pc. Choppa et al., MULTIPLEX PCR FOR THE DETECTION OF MYCOPLASMA-FERMENTANS, M-HOMINIS AND M-PENETRANS IN CELL-CULTURES AND BLOOD-SAMPLES OF PATIENTS WITH CHRONIC-FATIGUE-SYNDROME, Molecular and cellular probes, 12(5), 1998, pp. 301-308
Citations number
30
Categorie Soggetti
Biology,"Biochemical Research Methods","Biothechnology & Applied Migrobiology","Cell Biology
A multiplex polymerase chain reaction (PCR) was initially developed to
detect the presence of mycoplasma genus DNA sequences in cell culture
s and to differentiate between three human pathogenic mycoplasma speci
es simultaneously. The assay in turn, proved to be a useful tool for t
he detection of mycoplasma infection in human DNA samples. One set of
oligonucleotide primers which are specific for a highly conserved regi
on among all members of the genus mycoplasma along with three other pr
imer sets which are specific for Mycoplasma fermentans, Mycoplasma hom
inis and Mycoplasma penetrans species were used in this assay. The sen
sitivity of detection was determined by infecting peripheral blood mon
onuclear cells (PBMC) of healthy individuals with known bacterial copy
numbers from each species, extracting the DNA, and subjecting 1 mu g
of DNA from each sample to 40 cycles of amplification. By using agaros
e gel electrophoresis the detection level was determined to be 7, 7, 9
and 15 mycoplasma cells per mu g of human genomic DNA for M. genus, M
. fermentans, M. hominis and M. penetrans, respectively. The assay was
applied to DNA extracted from the PBMCs of individuals suffering from
chronic fatigue syndrome (CFS) (n=100) as determined by the Center fo
r Dlisease Control (CDC) criteria, and compared to healthy individuals
(n=100). The percentage of M. genus infection was found to be 52% in
CFS patients and only 15% in healthy individuals. Mycoplasma fermentan
s, M. hominis and M. penetrans were detected in 32, 9 and 6% of the CF
S patients while they were detected in 8, 3 and 2% of the healthy cont
rol subjects, respectively. This assay provides a rapid and cost effic
ient procedure to screen either cell cultures or clinical samples for
the presence of three potentially pathogenic species of mycoplasma wit
h a high level of sensitivity and specificity. (C) 1998 Academic Press
.